Azienda Sanitaria Territoriale Di Ascoli Piceno
- Address
- lock Available on a paid plan
Cardiovascular Diseases
At Azienda Sanitaria Territoriale Di Ascoli Piceno, research in cardiovascular disease focuses on better prevention and treatment for people with atrial fibrillation, hypertension, and established cardiovascular disease. These studies are designed to test new options that may reduce stroke risk, improve blood pressure control, and lower major heart-related complications.
- Preventing stroke and systemic embolism in atrial fibrillation
- Improving treatment for hypertension with high cardiovascular risk
- Evaluating therapies aimed at reducing heart failure and other cardiovascular events
The overall goal is to identify safer and more effective ways to protect patients at risk of serious cardiovascular events.
Hemic and Lymphatic Diseases
A major part of the site’s clinical trial activity centers on blood cancers and related disorders, including acute myeloid leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, follicular lymphoma, diffuse large B-cell lymphoma, multiple myeloma, and myelodysplastic syndromes. These studies often explore whether newer treatment combinations can improve remission rates, reduce residual disease, and extend progression-free survival.
- Testing new treatment strategies for leukemia and lymphoma
- Assessing approaches to achieve minimal residual disease negativity
- Studying therapies for newly diagnosed and relapsed hematologic malignancies
The research in this field reflects a strong focus on refining hematologic cancer care and improving outcomes for patients with difficult-to-treat disease.
Immune System Diseases
The site also participates in trials for immune-mediated conditions, with work that includes paroxysmal nocturnal hemoglobinuria and other disorders linked to abnormal immune activity. These studies aim to evaluate long-term safety, tolerability, and the effectiveness of therapies that may better control disease and reduce complications.
- Investigating treatments for paroxysmal nocturnal hemoglobinuria
- Evaluating longer-term safety and tolerability of immune-targeted therapies
- Exploring improved disease control in complement-related disorders
This area highlights interest in immune system research that may support more durable and better-tolerated treatment options.
Male Urogenital Diseases
Clinical research in this therapeutic area includes studies relevant to kidney disease, particularly end-stage kidney disease and treatment support for patients receiving peritoneal dialysis. The purpose of these trials is to improve the effectiveness and practicality of dialysis care while maintaining patient safety and treatment quality.
- Assessing dialysis solutions for better kidney replacement therapy
- Supporting care for end-stage kidney disease
- Improving treatment performance and patient convenience in dialysis
This research contributes to ongoing efforts in renal care and chronic disease management.
Neoplasms
The oncology portfolio at this hospital site includes trials across several cancers, especially leukemia, lymphoma, and multiple myeloma. These studies are generally aimed at testing new therapies, comparing treatment strategies, and improving response rates in both newly diagnosed and previously treated patients.
- Studying new treatment combinations for leukemia
- Comparing approaches for lymphoma and multiple myeloma
- Improving remission, survival, and disease control in cancer care
Overall, the research reflects a broad commitment to advancing oncology through more effective and better-tolerated treatment options.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 2 of 5 therapeutic areas and 15 of 76 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 72 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 9 by active trials.
lock +8 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +2 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 567 other sites in Italy
Therapeutic Area Benchmark — Italy
Select a therapeutic area to compare against other sites in Italy.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Italy
Market Share
Country: Italy
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Azienda Sanitaria Territoriale Di Ascoli Piceno
lock Showing 1 of 21 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY, VERSUS INVESTIGATOR’S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) | Regeneron Pharmaceuticals Inc. | Phase III | Not Recruiting | Jan 2024 | — |
IMP list
lock Showing 1 of 76 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Cyclophosphamide | 5 | Unknown | 2019-10-30 | 2024-01-23 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.